应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01276 恒瑞医药
已收盘 09-29 16:08:04
45.600
+0.840
+1.88%
最高
47.500
最低
44.860
成交量
553.32万
今开
44.980
昨收
44.760
日振幅
5.90%
总市值
3,026亿
流通市值
117.65亿
总股本
66.37亿
成交额
2.55亿
换手率
2.14%
流通股本
2.58亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
恒瑞医药：贝莱德减持，好仓比例降至6.96%
港股披露 · 17:32
恒瑞医药：贝莱德减持，好仓比例降至6.96%
诺和诺德加仓减重赛道，26亿美元买下恒瑞医药周口服减肥药
第一财经 · 15:58
诺和诺德加仓减重赛道，26亿美元买下恒瑞医药周口服减肥药
港股异动 | 恒瑞医药(01276.HK)午后拉升超5% 创新药海外授权诺和 潜在总交易额高达26亿美元
智通财经 · 13:36
港股异动 | 恒瑞医药(01276.HK)午后拉升超5% 创新药海外授权诺和 潜在总交易额高达26亿美元
加速出海！恒瑞医药口服GLP-1/GIP减重药授权诺和诺德，潜在交易额最高26亿美元
华尔街见闻 · 13:26
加速出海！恒瑞医药口服GLP-1/GIP减重药授权诺和诺德，潜在交易额最高26亿美元
创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%
金吾财讯 · 13:20
创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%
恒瑞医药直线拉升，现涨超3%
智通财经 · 13:06
恒瑞医药直线拉升，现涨超3%
恒瑞医药H股涨超5%
南方财经网 · 13:06
恒瑞医药H股涨超5%
恒瑞医药A股午后升逾 3%、H股急升逾4%，其将 HRS-1596海外独家权益许可给诺和，潜在交易额最高 26 亿美元
老虎资讯综合 · 13:03
恒瑞医药A股午后升逾 3%、H股急升逾4%，其将 HRS-1596海外独家权益许可给诺和，潜在交易额最高 26 亿美元
恒瑞医药(600276.SH)与Novo Nordisk A/S 签署HRS-1596项目授权许可协议
智通财经 · 12:45
恒瑞医药(600276.SH)与Novo Nordisk A/S 签署HRS-1596项目授权许可协议
恒瑞医药：将HRS-1596有偿许可给诺和 潜在总交易额最高可达26亿美元
格隆汇 · 12:34
恒瑞医药：将HRS-1596有偿许可给诺和 潜在总交易额最高可达26亿美元
恒瑞医药（01276）与诺和诺德达成HRS-1596全球许可协议 总交易额最高26亿美元
公告速递 · 12:30
恒瑞医药（01276）与诺和诺德达成HRS-1596全球许可协议 总交易额最高26亿美元
异动解读｜恒瑞医药盘中上涨3.57%，多家国际机构密集增持叠加新药审批加速
行情直击 · 09:55
异动解读｜恒瑞医药盘中上涨3.57%，多家国际机构密集增持叠加新药审批加速
恒瑞医药：UBS Group AG增持，好仓比例升至5.23%
港股披露 · 09-25
恒瑞医药：UBS Group AG增持，好仓比例升至5.23%
恒瑞医药：贝莱德增持，好仓比例升至7.32%
港股披露 · 09-25
恒瑞医药：贝莱德增持，好仓比例升至7.32%
恒瑞医药(01276)公布2026年第一次临时股东大会表决结果 六项议案全部获批
公告速递 · 09-24
恒瑞医药(01276)公布2026年第一次临时股东大会表决结果 六项议案全部获批
恒瑞医药（01276）2026年首次临时股东会审议六大议案全数获通过
公告速递 · 09-24
恒瑞医药（01276）2026年首次临时股东会审议六大议案全数获通过
恒瑞医药（01276）2026年第一次临时股东大会六大议案悉数通过
公告速递 · 09-24
恒瑞医药（01276）2026年第一次临时股东大会六大议案悉数通过
恒瑞医药：GIC Private Limited减持，好仓比例降至16.92%
港股披露 · 09-24
恒瑞医药：GIC Private Limited减持，好仓比例降至16.92%
异动解读｜恒瑞医药盘中下跌3.01%，制药板块集体走弱拖累股价
行情直击 · 09-24
异动解读｜恒瑞医药盘中下跌3.01%，制药板块集体走弱拖累股价
字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化
蓝鲸财经 · 09-23
字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化
公司概况
公司名称：
恒瑞医药
所属市场：
SEHK
上市日期：
--
主营业务：
江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":45.6,"timestamp":1790669284003,"preClose":44.76,"halted":0,"volume":5533215,"delay":0,"changeRate":0.01876675603217166,"floatShares":258000000,"shares":6637000000,"eps":1.3802451176549049,"marketStatus":"已收盘","change":0.84,"latestTime":"09-29 16:08:04","open":44.98,"high":47.5,"low":44.86,"amount":255244070,"amplitude":0.058981,"askPrice":45.62,"askSize":17000,"bidPrice":45.6,"bidSize":17400,"shortable":3,"etf":0,"ttmEps":1.3611673228507086,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790731800000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":44.76,"dividendRate":0.005007,"openAndCloseTimeList":[[1790645400000,1790654400000],[1790658000000,1790668800000]],"volumeRatio":2.151179,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":45.62,"timestamp":1790665200000,"preClose":44.47,"halted":0,"volume":79983100,"delay":0,"premium":"-14.55"}},"requestUrl":"/m/hq/s/01276/wiki","defaultTab":"wiki","newsList":[{"id":"1197604552","title":"恒瑞医药：贝莱德减持，好仓比例降至6.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197604552","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197604552?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:32","pubTimestamp":1790674325,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月24日在联交所场内以每股均价47.481港元卖出恒瑞医药股份49.06万股，涉资约2329.42万港元，属场内主动交易，即在二级市场直接买卖股份。贝莱德此次减持前持有恒瑞医药好仓1845.00万股，占比7.15%；减持后持股量为1795.94万股，好仓比例降至6.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671294288","title":"诺和诺德加仓减重赛道，26亿美元买下恒瑞医药周口服减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2671294288","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671294288?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:58","pubTimestamp":1790668739,"startTime":"0","endTime":"0","summary":"在2030战略目标未能打动资本市场背景下，诺和诺德转身加码并购减肥药管线。9月29日中午，恒瑞医药（600276.SH；01276.HK）宣布已与诺和诺德达成许可协议，将胰高血糖素样肽-1（GLP-1）和抑胃肽（GIP）双受体激动剂HRS-1596海外开发、生产和商业化独家权利授权给诺和诺德。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886468670.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886468670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828805.USD","BK0012","BK0183","THNR","LU2097828474.EUR","BK0239","LU0359201885.HKD","LU2097828714.EUR","LU2543165471.USD","LU1064131003.USD","LU0359201612.USD","LU2488822045.USD","LU1997245177.USD","BK1191","LU2097828557.USD","LU2097828631.EUR","LU2580892862.HKD","LU0359202008.SGD","LU1997244956.HKD","BK0196","BK0028","LU2328871848.SGD","LU1781817850.SGD","LU1820825898.SGD","BGIA","LU1969619763.USD","LU1997245094.SGD","01276","LU1655091616.SGD","LU1146622755.USD","LU2148510915.USD","LU0405327148.USD","600276","LU2580892789.USD","LU1064130708.USD","BK0060","LU2289578879.USD","BK0188","LU0405327494.USD","LU1328615791.USD","LU2495084118.USD","LU1580142542.USD","LU1023057109.AUD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671936782","title":"港股异动 | 恒瑞医药(01276.HK)午后拉升超5% 创新药海外授权诺和 潜在总交易额高达26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671936782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671936782?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:36","pubTimestamp":1790660165,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359201612.USD","BK1161","01276","LU0359201885.HKD","LU1023057109.AUD","06978","BK1191","BK1574","LU0359202008.SGD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293387","title":"加速出海！恒瑞医药口服GLP-1/GIP减重药授权诺和诺德，潜在交易额最高26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293387","media":"华尔街见闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293387?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:26","pubTimestamp":1790659609,"startTime":"0","endTime":"0","summary":"恒瑞医药股价直线拉升超3%，公司将自主研发的口服GLP-1/GIP双受体激动剂HRS-1596授权给诺和诺德，交易包括3亿美元首付款及最高23亿美元里程碑付款，并另收销售提成。HRS-1596有望实现每周一次口服给药，目前仍处早期临床阶段。恒瑞预计该交易将于2026年第四季度完成交割。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3782716","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","LU2580892789.USD","BK0028","BK0183","BK1191","LU1023057109.AUD","LU2580892862.HKD","LU1997245177.USD","LU2495084118.USD","LU0405327494.USD","LU2328871848.SGD","600276","LU1328615791.USD","BK0196","01276","BGIA","JDOC","LU2097828631.EUR","LU2097828557.USD","BK0060","LU0359201885.HKD","LU1064131003.USD","LU2097828805.USD","BK0239","LU1255011170.USD","LU2097828474.EUR","LU1580142542.USD","LU0359202008.SGD","LU1655091616.SGD","LU1820825898.SGD","BK0012","LU2148510915.USD","LU1064130708.USD","LU1997245094.SGD","LU0359201612.USD","LU2488822045.USD","LU1969619763.USD","BK0188","LU2289578879.USD","LU1146622755.USD","LU2543165471.USD","LU1781817850.SGD","LU2097828714.EUR","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1023057109.AUD","BK1587","BK1191","IE00BPRC5H50.USD","LU2476274308.USD","IBBQ","06955","LU0348827113.USD","LU0417516902.SGD","LU1961090484.USD","LU2488822045.USD","02162","MEDX","KURE","09926","LU1720050803.USD","159992","LU0417516738.SGD","BK1583","LU0561508036.HKD","06978","LU2543165471.USD","02157","BK1588","LU1969619763.USD","LU2476274720.SGD","09995","LU0359201885.HKD","LU0196878994.USD","LU2328871848.SGD","LU0348766576.USD","LU2778985437.USD","LU0348735423.USD","LU0348767384.USD","BK1574","LU0359201612.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","09688","LNGR","LU0348784397.USD","LU0359202008.SGD","LU1794554557.SGD","01276","06990","LU0348825331.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298463","title":"恒瑞医药直线拉升，现涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671298463?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:06","pubTimestamp":1790658393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["600276","LU1781817850.SGD","LU2097828474.EUR","LU0405327494.USD","LU2328871848.SGD","LU2097828631.EUR","01276","LU1969619763.USD","LU2097828805.USD","BK0239","BK0188","LU0405327148.USD","LU1064131003.USD","LU2097828557.USD","BK0028","LU1328615791.USD","LU2495084118.USD","LU1255011170.USD","BK0060","LU1146622755.USD","LU2488822045.USD","LU2289578879.USD","LU2148510915.USD","LU1064130708.USD","BK0012","BK0183","LU2097828714.EUR","LU1580142542.USD","BK0196","LU1997245177.USD","LU1655091616.SGD","LU1820825898.SGD","LU2580892862.HKD","LU1997244956.HKD","LU1997245094.SGD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298785","title":"恒瑞医药H股涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298785","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671298785?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:06","pubTimestamp":1790658360,"startTime":"0","endTime":"0","summary":"南方财经9月29日电，恒瑞医药H股涨超5%，公司与诺和签署HRS-1596项目授权许可协议，潜在总交易额最高达26亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886352732.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886352732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","LU1255011170.USD","LU1655091616.SGD","600276","BK0060","LU2328871848.SGD","LU2097828805.USD","LU1997245177.USD","LU2097828631.EUR","LU2097828714.EUR","BK0188","LU2495084118.USD","LU1146622755.USD","LU1969619763.USD","LU2580892862.HKD","LU2543165471.USD","LU1064131003.USD","LU0405327494.USD","LU2148510915.USD","LU1781817850.SGD","LU2097828474.EUR","LU2097828557.USD","LU1064130708.USD","LU2580892789.USD","BK1191","LU2488822045.USD","LU0359201612.USD","01276","LU1023057109.AUD","LU0405327148.USD","LU1580142542.USD","LU1997245094.SGD","BK0028","LU0359202008.SGD","BK0196","BK0239","LU1997244956.HKD","LU2289578879.USD","BK0183","LU0359201885.HKD","LU1328615791.USD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129270564","title":"恒瑞医药A股午后升逾 3%、H股急升逾4%，其将 HRS-1596海外独家权益许可给诺和，潜在交易额最高 26 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129270564","media":"老虎资讯综合","labels":["movement"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129270564?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:03","pubTimestamp":1790658239,"startTime":"0","endTime":"0","summary":"恒瑞医药 A 股午后升逾 3%、H 股午后急升逾 4%。诺和将获得 HRS-1596 在大中华地区以外的全球范围内开发、生产和商业化的独家权利。该交易的潜在总交易额最高可达 26 亿美元，包括 3 亿美元首付款以及达成相关开发、注册和商业化里程碑后获得的付款。此外，恒瑞将有资格根据 HRS-1596 在授权区域内的净销售额收取相应的销售提成。据悉，HRS-1596 是一款恒瑞自主研发的 GLP-1/GIP 双受体激动剂。恒瑞已在中国获准开展 HRS-1596 用于体重管理和 2 型糖尿病的Ⅰ期临床试验。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"恒瑞医药将 HRS-1596海外独家权益许可给诺和，潜在交易额最高 26 亿美元","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2671298682","title":"恒瑞医药(600276.SH)与Novo Nordisk A/S 签署HRS-1596项目授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298682","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671298682?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:45","pubTimestamp":1790657103,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，公司与Novo Nordisk A/S公司达成协议，将恒瑞潜在每周一次口服给药的胰高血糖素样肽-1和抑胃肽双受体激动剂HRS-1596有偿许可给诺和。此外，恒瑞将有资格根据HRS-1596在授权区域内的净销售额收取相应的销售提成。恒瑞已在中国获准开展HRS-1596用于体重管理和2型糖尿病的Ⅰ期临床试验。该协议的签署有助于拓宽HRS-1596的海外市场，为全球患者提供优质的治疗选择，也将进一步提升公司创新品牌和海外业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU1655091616.SGD","BK4588","LU1255011170.USD","BK0239","LU1328615791.USD","LU1820825898.SGD","BK0012","LU2097828631.EUR","LU2289578879.USD","01276","LU2580892862.HKD","BK0196","LU1064131003.USD","BK0183","LU2488822045.USD","LU1997245094.SGD","LU2148510915.USD","PPH","LU2097828557.USD","LU2097828474.EUR","BK4532","BK4599","LU2097828805.USD","LU2328871848.SGD","LU1580142542.USD","LU0405327494.USD","LU0405327148.USD","LU1146622755.USD","BK0188","IE00BKVL7J92.USD","LU1997244956.HKD","OZEM","IE00BZ1G4Q59.USD","LU1781817850.SGD","NVOH","THNR","LU1997245177.USD","LU0154236417.USD","NVOX","BK4007","BK0028","NVOC","BK0060","BK4585","LU1969619763.USD","LU1093756325.SGD","LU2097828714.EUR","LU1064130708.USD","LU2495084118.USD","LU2580892789.USD","LU1093756168.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298849","title":"恒瑞医药：将HRS-1596有偿许可给诺和 潜在总交易额最高可达26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298849","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671298849?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:34","pubTimestamp":1790656460,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2097828557.USD","LU0359201612.USD","BK1191","LU1655091616.SGD","LU1997245177.USD","LU2495084118.USD","LU2097828474.EUR","BK0196","LU1146622755.USD","LU1328615791.USD","LU1820825898.SGD","LU2148510915.USD","LU0405327494.USD","LU1997245094.SGD","LU2328871848.SGD","LU2289578879.USD","LU1064130708.USD","LU2543165471.USD","LU2097828714.EUR","LU1969619763.USD","BK0183","LU2580892862.HKD","LU2488822045.USD","LU1064131003.USD","LU2580892789.USD","01276","BK0028","LU0405327148.USD","LU1255011170.USD","LU1023057109.AUD","BK0239","BK0188","BK0060","LU0359201885.HKD","LU1997244956.HKD","LU1781817850.SGD","LU2097828631.EUR","LU1580142542.USD","BK0012","LU0359202008.SGD","600276","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190603262","title":"恒瑞医药（01276）与诺和诺德达成HRS-1596全球许可协议 总交易额最高26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190603262","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190603262?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:30","pubTimestamp":1790656255,"startTime":"0","endTime":"0","summary":"江蘇恒瑞醫藥股份有限公司（01276）9月29日公告称，已与Novo Nordisk A/S（下称“诺和诺德”）签署《HRS-1596项目授权许可协议》。恒瑞将其自主研发的胰高血糖素样肽-1/抑胃肽（GLP-1/GIP）双受体激动剂HRS-1596在大中华地区（中国大陆、香港、澳门及台湾地区）以外的全球开发、生产及商业化独家权利，有偿许可予诺和诺德。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142161345","title":"异动解读｜恒瑞医药盘中上涨3.57%，多家国际机构密集增持叠加新药审批加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1142161345","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142161345?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:55","pubTimestamp":1790646936,"startTime":"0","endTime":"0","summary":"9月29日，恒瑞医药盘中上涨3.57%，报46.32港元，成交额3388.57万港元。消息面上，近期多家国际头部机构密集增持恒瑞医药H股。瑞银集团9月21日场内买入约206.68万股，好仓比例升至5.23%；贝莱德9月22日再度增持约195.98万股，好仓比例升至7.32%；此前美国资本集团亦有约57.89万股增持动作。此外，花旗及美银均维持对恒瑞医药的积极评级，看好创新药政策红利及全球化出海前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药上涨，国际机构密集增持","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134106618","title":"恒瑞医药：UBS Group AG增持，好仓比例升至5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134106618","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134106618?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:15","pubTimestamp":1790327705,"startTime":"0","endTime":"0","summary":"UBS Group AG于2026年9月21日在联交所场内以每股均价48.8574港元买入恒瑞医药H股206.68万股，涉资约1.01亿港元。该笔交易属场内主动交易，即在二级市场直接买卖股份。UBS Group AG此次增持前持有恒瑞医药好仓1142.98万股，占比4.43%；增持后持股量为1349.66万股，好仓比例升至5.23%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164791918","title":"恒瑞医药：贝莱德增持，好仓比例升至7.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164791918","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164791918?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:14","pubTimestamp":1790327698,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月22日通过取得股份保证权益的方式增持恒瑞医药（01276）H股195.98万股。该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有恒瑞医药好仓1693.68万股，占比6.56%；增持后持股量为1889.65万股，好仓比例升至7.32%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126193484","title":"恒瑞医药(01276)公布2026年第一次临时股东大会表决结果 六项议案全部获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1126193484","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126193484?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:22","pubTimestamp":1790252540,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司9月24日披露，其2026年第一次临时股东大会已顺利召开并完成表决，会议审议的全部6项议案均获通过。本次股东大会召开日期为2026年9月24日，现场及在线出席的股东及授权代表共8,544人，代表可投票股份3,778,887,487股，占公司有表决权股份总数的57.0332%。其中，A股股东出席人数8,543人，代表3,650,537,574股，占55.0961%；H股股东1人，代表128,349,913股，占1.93713%。恒瑞医药董事会主席孙飘扬在公告中确认，以上决议的表决结果合法、有效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155919125","title":"恒瑞医药（01276）2026年首次临时股东会审议六大议案全数获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1155919125","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155919125?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:55","pubTimestamp":1790250939,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2026年9月24日在上海市浦东新区海科路1288号公司会议室召开2026年第一次临时股东大会。会议由董事会召集并由董事长孙飘扬先生主持，采用现场投票与网络投票相结合的方式进行。国浩律师（南京）事务所出具的法律意见书确认，本次会议的召集、召开及表决程序符合中国《公司法》等相关法规及公司章程的规定，所作决议合法有效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165314108","title":"恒瑞医药（01276）2026年第一次临时股东大会六大议案悉数通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1165314108","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165314108?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:55","pubTimestamp":1790250938,"startTime":"0","endTime":"0","summary":"2026年9月24日，恒瑞医药在上海市浦东新区海科路1288号公司会议室召开2026年第一次临时股东大会。会议采取现场与网络相结合的方式进行，并对全部议案逐项表决。国浩律师（南京）事务所出具的法律意见书确认，会议的召集、召开及表决程序符合法律法规和《公司章程》规定，表决结果合法有效。本次股东大会由公司第十届董事会第四次会议决议召集。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199077625","title":"恒瑞医药：GIC Private Limited减持，好仓比例降至16.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199077625","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199077625?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:18","pubTimestamp":1790241517,"startTime":"0","endTime":"0","summary":"2026年9月21日，GIC Private Limited在联交所场内以每股均价47.8372港元卖出恒瑞医药（01276）H股21.42万股，涉资约1024.67万港元，该笔交易属场内主动交易，即在二级市场直接买卖股份。GIC Private Limited此次减持前持有恒瑞医药好仓4390.18万股，占比17.0%；减持后持股量为4368.76万股，好仓比例降至16.92%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110718818","title":"异动解读｜恒瑞医药盘中下跌3.01%，制药板块集体走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1110718818","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110718818?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:26","pubTimestamp":1790216761,"startTime":"0","endTime":"0","summary":"9月24日，恒瑞医药盘中下跌3.01%，报45.8港元，成交额3687.62万港元。公司所在制药板块整体承压，石药集团跌2.07%、中国生物制药跌2.46%、翰森制药跌2.92%、凯莱英跌4.96%，行业个股普遍走弱。此外，1类创新药SHR-2004注射液上市申请已获药监局受理，员工持股计划亦在推进中。尽管基本面催化不断，短期股价仍受板块整体回调拖累。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"恒瑞医药随制药板块走弱，创新药管线利好不断","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669762483","title":"字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2669762483","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669762483?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:01","pubTimestamp":1790164907,"startTime":"0","endTime":"0","summary":"截图来源于港股公告叠加字节跳动将AI制药业务独立拆分设立Anew Labs这一动作，入局AI制药的大厂阵营还在持续扩容。目前，行业已有落地成果佐证AI的前端价值。港股龙头英硅智能的发展路径，展现了当前AI药企的部分商业化现状。截图来源于港股公告这份增速亮眼的财报，证明AI技术具备即时商业变现能力。AI技术模型可以加快新药研发的起点，但从这条赛道跑出来的玩家，大概率是率先实现临床转化与商业化落地的那个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789979347715387090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4574","BK0028","LU2488822045.USD","LU2097828631.EUR","IE00B0JY6N72.USD","LU0359201612.USD","LU0359202008.SGD","LU0405327148.USD","NVOH","BK4548","LU1781817850.SGD","BK4579","BK0239","BK4526","LU1969619763.USD","01276","LU1328615791.USD","BIDU","LU1997245094.SGD","BK4599","BK0188","BK4552","LU0405327494.USD","BK4602","LU2580892862.HKD","BK4504","LU2495084118.USD","THNR","LU0173614495.USD","LU1255011170.USD","LU2328871848.SGD","LU1093756168.USD","LU1023057109.AUD","BK4007","BK4532","LU2289578879.USD","BK0196","BK4543","BK4077","LU1146622755.USD","LU1093756325.SGD","LU2097828557.USD","02257","IE00BZ1G4Q59.USD","LU0640798160.USD","LU2148510915.USD","NVOX","PPH","BK4585","BIDG","BK0060","LU2097828805.USD","600276","LU1655091616.SGD","09888","LU1580142542.USD","LU2580892789.USD","BK4587","BK4535","LU2097828474.EUR","LU0154236417.USD","DRGN","LU1115378108.SGD","OZEM","KBDU","NVOC","LU1064131003.USD","BK4614","BK4588","BK4514","LU0287142896.SGD","BK1161","IE00BKVL7J92.USD","LU1064130708.USD","BK4531","LU2097828714.EUR","BK4612","LU1997245177.USD","LU1820825898.SGD","LU1997244956.HKD","NVO","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0939},{"period":"1month","weight":-0.0663},{"period":"3month","weight":-0.2263},{"period":"6month","weight":-0.3286},{"period":"1year","weight":-0.4855},{"period":"ytd","weight":-0.3696}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}